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Background: Lipoprotein glomerulopathy (LPG) is a rare inherited renal disease characterized by intraglomerular
lipoprotein within the lumina of severely dilated glomerular capillaries. The common clinical presentation of LPG
includes proteinuria or nephrotic syndrome. Hypertension and anemia were thought to be mild in LPG. Thrombotic
microangiopathy (TMA) in LPG has not been previously reported. In this report, we present a patient with LPG that
developed TMA. To the best of our knowledge, this is the first report of TMA in LPG.
Case presentation: Four years ago (2005), a 19-year-old Chinese woman was diagnosed with nephrotic syndrome
and provided prednisone treatment. A combination of prednisone and cyclophosphamide did not have any effect
and was discontinued after six months. Although she was steroid-resistant, over the next subsequent three years,
she maintained normal renal function without anemia and thrombocytopenia. In February 2009, she had a severe
headache and blurry vision and presented at a local hospital with severe hypertension. Blood pressure was 220/
160 mmHg. Laboratory data showed hemoglobin 3.8 g/dL; platelet counts 29×109/L; urinary protein 7.90 g/d; total
bilirubin 29.9 umol/L; indirect bilirubin 28.2 umol/L; LDH 1172 U/L; ALB 2.66 g/dL; urea nitrogen 52 mg/dL; serum
creatinine 3.2 mg/dL; triglyceride 253 mg/dL; total cholesterol 273 mg/dL. ANA, ds-DNA, ANCA, anti-GBM antibody
and anticardiolipin were all negative. A renal biopsy revealed LPG with TMA. Genetic evaluation showed the patient
carried the APOE Kyoto mutation. Adequate control of blood pressure improved microangiopathic anemia and
thrombocytopenia, however, renal function did not improve and she eventually developed uremia and became
hemodialysis dependent.
Conclusion: We report on a rare case of TMA probably due to malignant hypertension in LPG. Early lipid-lowering
and antihypertensive treatment may improve outcome. The pathophysiologic relationship between LPG and TMA
should be investigated further.
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Lipoprotein glomerulopathy (LPG) is a rare inherited renal
disease characterized by the presence of intraglomerular
lipoprotein thrombi due to deposition of lipid droplets
within the lumina of severely dilated glomerular capillaries,
with a variable degree of mesangial proliferation and seg-
mental glomerular sclerosis [1,2]. The common clinical
presentation of LPG includes proteinuria or nephrotic* Correspondence: hzxawy@scu.edu.cn
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reproduction in any medium, provided the orsyndrome, which may gradually progress to chronic renal
failure. Despite deposition of numerous intraglomerular
lipoprotein thrombi, no thrombi in arterioles have been
described in LPG patients. Moreover, acute renal failure
has rarely developed in LPG patients. In the report herein,
we present a case of LPG with thrombotic micro-
angiopathy (TMA). The relationship between LPG and
TMA is discussed.
Case presentation
A 19-year-old Chinese woman was admitted to our hos-
pital in April 2009. Four years prior to this admission,
she noticed mild pretibial edema. At that time, urinalysis. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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was diagnosed with nephrotic syndrome. Oral prednis-
one was initiated for 2 months with a dosage of 1 mg/kg
per day, then tapered. The total period of prednisone
treatment was 6 months. During this period, cyclophos-
phamide 100 mg per day orally was added for 10 days.Figure 1 (See legend on next page.)The total cyclophosphamide dosage was 1 g. The patient
did not improve with this regimen. During the next 3 years
(2005–2008), she maintained stable renal function and
normal blood pressure. Six months before admission
(November 2008), hypertension developed at 150/90 -
mmHg. The 24-hour urinary protein was 8.8 g/d.
(See figure on previous page.)
Figure 1 Glomerular and vascular findings from renal biopsy specimens in a patient with LPG and TMA. Panel A shows a glomerulus
with the presence of intraglomerular lipoprotein thrombi due to deposition of lipid droplets within the diluted lumina of glomerular capillaries.
Although lipoprotein thrombi were present in glomerular capillaries, the glomerulus still exhibited ischemic features (HE staining; ×200). In Panel
B, the glomerulus shown in Panel A were enlarged (HE staining; ×400). In Panel C, glomeruli shown in Panel A were stained in PAS, also showing
intraglomerular lipoprotein thrombi and ischemic features (PAS staining; ×200). In Panel D, lipid was stained positive (Oil Red O staining; ×400). In
Panel E, a thrombus in the lumina of arteriole which extended to the vascular pole of the adjacent ischemic glomerulus is shown. Other
arterioles also showed thrombus and pronounced swelling of endothelial cells (PAS staining; ×200). In Panel F, the thrombus in the arteriole
extended to the vascular pole of an adjacent ischemic glomerulus shown in Panel E was enlarged (PAS staining; ×400). In Panel G, a glomerulus
was shown with an extensive double-contour formation. Few red blood cells are observed in the capillaries. Adjacent arterioles with a swelling of
endothelial cells and the presence of a fluffy material (fibrin) that caused a narrowing of vascular lumen are shown (PASM staining; ×400). In
Panel H, endothelial swelling with mucoid change and chunks of fibrin in interlobular arteries are shown. In Panel I, the capillary lumen were
occluded with various granule sizes. In Panel J, the subendothelial zone was focally expanded by electron-lucent material, and a new glomerular
basement membrane was formed. Panels I & J are electron microscopy images.
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http://www.biomedcentral.com/1471-2369/14/53Laboratory findings showed a serum total protein of
4.23 g/dL, serum albumin 2.46 g/dL, triglyceride 241 mg/
dL, total cholesterol 350 mg/dL, HDL-C 71 mg/dL, and
LDL-C 233 mg/dL. A complete blood count showed a
hemoglobin of 9.8 g/dL, WBC counts 6.6×109/L, and
platelet counts 130×109/L. Felodipine 5 mg per day was
administered to keep blood pressure at a normal range.
Just two months before admission (February 2009), she
felt a severe headache, blurry vision, nausea, vomiting, and
presented to a local hospital. On admission at that hos-
pital, physical examination showed blood pressure was up
to 220/160 mmHg, with facial pallor, and pitting edema
of the lower extremities. Laboratory data showed a
hemoglobin of 3.8 g/dL; WBC counts 3.75 × 109/L; plate-
let counts 29 × 109/L; urinary protein 7.90 g/d; total biliru-
bin 29.9 umol/L; indirect bilirubin 28.2 umol/L; ALT 22
U/L; AST 36 U/L; LDH 1172 U/L; ALB 2.66 g/dL; urea ni-
trogen 52 mg/dL; serum creatinine 3.2 mg/dL; triglyceride
253 mg/dL; total cholesterol 273 mg/dL, HDL-C 46 mg/
dL, LDL-C 200 mg/dL, VLDL-C 50 mg/dL, apoA1
0.90 mg/dL, apoB 1.21 mg/dL. ANA, ds-DNA, ANCA,
anti-GBM antibody and anticardiolipin were all negative.
HIV, HBV and HCV tests were all negative. Urine HCG
was negative. A brain CT scan did not reveal any abnor-
mality. The patient did not have any evidence of malig-
nancy, pregnancy or abortion. During this period, she had
not experienced diarrhea or infections. There was no fam-
ily history of renal diseases, hypertension or hematologic
diseases.
A kidney biopsy was performed. Light and electron
microscopic examinations of renal biopsy material showed
a marked dilatation of the capillary lumen in the glomeruli,
and the presence of laminated intraglomerular lipoprotein
thrombi due to deposition of lipid droplets within the
glomerular capillaries (Figure 1A,B,C). Immunofluores-
cence showed IgG, IgA, IgM, C3, C4, C1q were all nega-
tive. Oil Red O staining was positive (Figure 1D). Electron
microscopy showed that the glomerular capillary lumina
were occupied by granules of various sizes (Figure 1I). She
was diagnosed with LPG and treated with antihypertensivedrugs (Nifidipine 60 mg + Prazosin 12 mg +Metoprolol
50 mg per day) and Simvastatin. At the same time, she
received hemodialysis and red blood cell transfusion. Over
the next four weeks, blood pressure was observed to be
under control (average level 135/80 mmHg). Anemia
and thrombocytopenia were improved. Hemoglobin was
7.8 g/dL, platelet counts were 110 × 109/L; albumin also
increased to 3.17 g/dL; but renal insufficiency was
aggravated, with urea nitrogen 24 mg/dL, and serum cre-
atinine 7.2 mg/dL. Urine output decreased progressively to
anuria. The patient was then transferred to our hospital.
Because LPG has rarely developed into irreversible
acute renal failure, a re-examination of the renal biopsy
specimens was performed. Among the 17 glomeruli
sampled for light microscopy, three were globally scler-
otic, and one was segmental sclerotic. The size of the
glomeruli varied greatly. The seven greatly-enlarged
glomeruli showed severe dilated capillaries filled with a
foamy, whorled, mesh-like material in the glomerular ca-
pillary lumens. The other six moderately-enlarged glom-
eruli showed extensive ischemic changes, retraction of
the glomerular tuft and marked thickening and wrink-
ling of the capillary wall (Figure 1A,B,C). Even in the is-
chemic glomeruli, a thrombus-like material was
observed in some capillaries, so the sizes of these glom-
eruli were still larger than normal glomeruli, which
made the ischemic appearance of these glomeruli hard
to identify. Double-contour formations were obvious.
Vascular lesions were severe. Swelling of endothelial cells
and fluffy masses (fibrin) in arterioles caused narrowing
and closure of vascular lumens (Figure 1E,F,G,H).
Thrombosis was found in the arterioles, and it extended
to the vascular pole of the adjacent ischemic glomerulus,
without inflammatory cell infiltration (Figure 1E,F).
Under electron microscopy, the glomerular capillaries
contained large, intraluminal, finely vacuolated extracel-
lular masses. The vacuoles were predominantly electron
lucent, suggesting lipid “thrombi.” The subendothelial
zone was focally expanded by electron-lucent material
(Figure 1I,G). LPG with TMA was diagnosed. In our
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exudates in both retinas. Serum apoE was 7.2 mg/dL.
Serum ADAMTS13 and fecal Shiga toxin were not
measured. Although she received fenofibrate (200 mg
per day), hemodialysis, antihypertensive therapy and
other supportive therapy, renal failure could not be
improved.
Genomic DNA of the patient was extracted from periph-
eral blood lymphocytes using DNA-isolation kits (TaKaRa,
Ostu, Japan). The patient, her sister, and her mother were
screened for mutations in the coding sequence of APOE.
Four pairs of primers (see Additional file 1: Appendix Table
S1) were designed with Primer Premier 5.0 to amplify all
exons and adjacent intron/exon boundaries of APOE
(reference sequence GenBank accession no. NM_000041).
PCR products containing the sequences of exons 1, 2, and
3 were sequenced directly in both directions, and that of
exon 4 was cloned into the pGEM-T vector (Promega,
Madison, WI), and sequenced on an ABI377A DNA se-
quencer (Applied Biosystems, Foster City, CA). APOE
Kyoto mutation was identified (Figure 2A). Family study
(Figure 2B,C) showed that her mother also carried the
APOE Kyoto mutation, but she did not present any
evidence of renal dysfunction, proteinuria or thrombo-
cytopenia. Restriction fragment length polymorphismFigure 2 Mutation Detection, Genotyping of ApoE and Family Pedigr
Panel A shows DNA sequencing results of APOE exon 3 of the patient and
(arrow). The LPG patient had a heterozygous C→T mutation leading to an
shows the results of APOE Kyoto detection with PCR-RFLP analysis. Lanes 1
207 bp fragments indicate heterozygous mutation of APOE Kyoto. Lanes 2
fragment indicates the wild-type homozygote. M: 100 bp molecular ladder
Lanes 1 (the patient), 2 (patient’s sister), and 4 (patient’s mother): the prese
genotype. Lanes 3 (control): the presence of 91 bp, 83 bp, 48 bp, 38 bp an
marker. In Panel C, family pedigree for the patient indicates the APOE Kyoto
DNA was available. No other family members had clinical evidence of the d
shading indicates patients with LPG. The patient’s mother is an asymptoma(RFLP) analysis for APOE genotype [3] showed these APOE
Kyoto mutations were located in ε3 (Figure 2D). Her sister
did not carry APOE Kyoto. Written informed consents
were obtained from the patient and her relatives prior to
commencement of the genetic analysis.
Conclusions
Lipoprotein glomerulopathy (LPG) is a rare inherited
kidney disease, mainly caused by the APOE mutation.
Less than 80 cases have been reported worldwide since
1989 [4], mainly among persons of Japanese and Chinese
origin. Affected patients typically present with nephrotic
syndrome, hypertriglyceridemia and elevated plasma
apoE levels. Hypertension had been thought to be mild
[5]. Approximately half of the reported cases in the lit-
erature developed renal failure 1–27 years after onset of
disease [6]. Risk factors hastening the progression of
LPG have not been clearly identified. On kidney biopsy,
intraglomerular lipoprotein thrombi due to deposition of
lipid droplets within the lumina of severely dilated glom-
erular capillaries are the distinct finding for this disease.
However, no thrombi in arterioles have been described.
TMA has not been previously reported in LPG.
Our case demonstrated LPG and TMA. The patient
presented nephrotic syndrome with elevated triglycerideees of Patients with Lipoprotein Glomerulopathy (LPG) and TMA.
a healthy control and the positions of the APOE Kyoto mutation
amino acid substitution of Cys for Arg at codon 25 of apoE. Panel B
(the patient) and 4 (patient’s mother): the presence of 274 bp and
(patient’s sister), 3 and 5 (healthy control): the presence of the 207 bp
. Panel D shows the results of genotyping with PCR-RFLP analysis.
nce of 91 bp, 48 bp, 38 bp and 35 bp fragments indicates an ε3/3
d 35 bp fragments indicates an ε2/3 genotype. M: pUC19 DNA/MspI
genotype in probands (arrows) and family members from whom
isease. Men are represented by squares, and women by circles. The
tic APOE Kyoto carrier.
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biopsy material showed a marked dilatation of the capil-
lary lumen in glomeruli with a mesh-like material. Elec-
tron microscopy confirmed the presence of extensive lipid
thrombi in capillary lumen. LPG had been diagnosed.
However, it is hard to attribute acute renal dysfunction,
severe anemia and thrombocytopenia to typical LPG.
Light and electron microscopic examinations of renal bi-
opsy material showed arteriole thrombosis, endothelial
swelling of arterioles, fibrin exudation in the lumina of
arterioles, glomerular shrinkage and widening of the
subendothelial zone. These thrombi in arterioles were dif-
ferent from lipo-thrombi in glomerular capillaries. The
former was stained PAS positive, while the latter had a
pale color with PAS and pale green with Masson’s tri-
chrome. These thrombi in arterioles should not be the re-
sult of a direct deposition of abnormal lipoprotein. Based
on elevated blood pressure, acute renal failure, elevated in-
direct bilirubin and LDH, thrombocytopenia and these
renal pathologic findings, LPG with TMA was diagnosed,
which has not been previously described in any LPG
patient.
TMA is characterized by a syndrome of microan-
giopathic hemolytic anemia, thrombocytopenia, and vari-
able signs of organ injury due to platelet thrombosis in the
microcirculation [7]. TMA usually encompasses hemolytic
uremia syndrome (HUS) and thrombotic thrombocyto-
penic purpura (TTP). TMA can be caused under some
predisposing conditions, such as pregnancy, cancer [8],
hematopoietic stem cell transplantation [9], HIV infection,
systemic lupus erythematosus [10], scleroderma, cyclo-
sporine or antineoplastic treatment [11-13] and malignant
hypertension [14,15], which are classified as secondary
forms of TMA. It is difficult to distinguish among these
diagnoses without clinical information.
Malignant hypertension was defined as severe elevation
of mean arterial pressure in combination with grade III to
IV hypertensive retinopathy, according to the Keith-
Wagener and Barker classification. It is often accompanied
by target organ damage, such as visual disturbances, head-
ache, heart failure, stroke or transient ischemic attack,
acute renal dysfunction. TMA was observed in 27% of
patients with malignant hypertension at the emergency de-
partment [16]. The pathogenesis of TMA in malignant
hypertension is not precisely understood. It is postulated
that the endothelial dysfunction caused by activation of the
renin-angiotensin-aldosterone system (RAAS) has a central
role. Reduction of NO and activation of a coagulation cas-
cade leads to fibrinoid necrosis, edema of arterioles and
local platelet aggregation. Microangiopathic hemolysis has
been attributed to the mechanical stress when red blood
cells pass through the narrowed lumen of arterioles. Rapid
control of hypertension could ameliorate TMA and con-
tribute to the improvement of renal function [16].In this case, the patient suffered severe headache, blurry
vision, nausea, vomiting, acute renal failure, grade III
hypertensive retinopathy, and microangiopathic hemolytic
anemia with blood pressure 220/160 mmHg. Thromb-
ocytopenia, anemia and elevated LDH improved with
blood pressure control. All of the above supported the pa-
tient suffered TMA which could be triggered by malignant
hypertension. Preexisting renal parenchymal diseases were
identified in 14% patients of malignant hypertension [16].
It is reasonable to presume that malignant hypertension
was triggered by uncontrolled LPG in this patient.
Most patients with TMA due to malignant hypertension
have platelet counts of over 50 × 109/L and hemoglobin of
over 6.5 g/dl [16-18]. In this case, the patient showed
severe anemia (3.8 g/dL) and thrombocytopenia (29 ×
109/L), which is very rare in TMA due to malignant hyper-
tension. As is known, there is a considerable amount of
lipoprotein thrombi in intraglomerular capillaries in LPG,
and blood passes through the narrow space between the
capillary wall and thrombus (Figure 1). We presume that
in malignant hypertension, the above mentioned lipopro-
tein thrombi led red blood cells to be more vulnerable to
shear stress, which could aggravate microangiopathic
hemolysis and worsen renal function. However, in view of
severe thrombocytopenia and anemia in this patient and
limited LPG cases reported, the connection between
LPG and TMA may be coincidental and need further
investigation.
Malignant hypertension with TMA is a medical emer-
gency. Its outcome depends on adequate control of blood
pressure and serum creatinine on presentation [19]. For
this case, the control of hypertension ameliorated micro-
angiopathic hemolytic anemia, but did not improve renal
failure. For LPG patients, early renal biopsy is crucial, be-
cause an early accurate diagnosis and treatment of LPG
shows remission and survival benefit. Protein A immu-
noadsorption [20] and LDL-apheresis [21] could induce
remission of LPG, but are very expensive. Treatment with
intensive lipid-lowering agents, including fibrates, has
been reported to lead to clinical remission along with
histological resolution of lipoprotein thrombi in serial bi-
opsies [22-25]. Clinical remission of LPG may reduce the
risks of malignant hypertension with TMA. Therefore,
early biopsy, effective treatment (fibrate-containing treat-
ment), and adequate control of blood pressure are import-
ant to improving the outcome of LPG.
Previous literature has not reported that cyclophos-
phamide alone with moderate dosage can induce TMA
[26,27]. This patient only received cyclophosphamide
with a total dosage of 1 g and had maintained stable
renal function, normal hemoglobin and platelet count
over the next three years. Therefore, for this patient,
cyclophosphamide did not appear to be the cause of
TMA three years later.
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http://www.biomedcentral.com/1471-2369/14/53In summary, we report herein a rare case of LPG that
developed severe TMA due to malignant hypertension.
Adequate control of blood pressure ameliorated micro-
angiopathic hemolytic anemia, but not renal failure. For
LPG, early diagnosis and treatment may lower the risk of
malignant hypertension with TMA. The factors that may
trigger this course and how patients should be treated has
not yet been determined. Careful observations of renal tis-
sue under light and electronic microscopy, especially for
arterioles are key to diagnosing LPG with TMA.
Consent
Written informed consents were obtained from the pa-
tient and her relatives for publication of this case report
and any accompanying images.
Additional file
Additional file 1: Appendix Table S1. Primer Sequences, Annealing
Temperatures, and Product Sizes of the PCR Products.
Abbreviations
LPG: Lipoprotein glomerulopathy; TTP: Thrombotic thrombocytopenic
purpura; HUS: Hemolytic uremic syndrome; TMA: Thrombotic
microangiopathy.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
YW, XHC, BHW, XXL, YT, PF, ZXH were the physicians treating the patient in
this report. BHW and ZXH performed the renal biopsy evaluation and the
pathology studies. YY performed genetic studies. The manuscript was
prepared by YW, XHC, BHW, YY, YT, PF and ZXH. All authors participated in
discussions about the manuscript and approved the final version.
Acknowledgements
This work was supported by grants from the National Key Technologies R&D
program (Grant number: 2006BAI05A08, PR. China), the National Natural
Science Foundation of China (81100330/H0801) and Sichuan Province Key
Technologies R&D program (Grant number: 2009SZ0143, 2010FZ0046).
Author details
1Department of Hematology, West China Hospital, National Key Laboratory
of Biotherapy of Human Diseases, Sichuan University, Chengdu, Sichuan
Province, China. 2Department of Nephrology, West China Hospital, National
Key Laboratory of Biotherapy of Human Diseases, Sichuan University,
Chengdu, Sichuan Province, China. 3Department of Medical Genetics, West
China Hospital, National Key Laboratory of Biotherapy of Human Diseases,
Sichuan University, Chengdu, Sichuan Province, China. 4Department of
Nephrology, Nuclear industry 416 Hospital, Chengdu, Sichuan Province,
China.
Received: 8 September 2012 Accepted: 13 February 2013
Published: 28 February 2013
References
1. Liberopoulos E, Siamopoulos K, Elisaf M: Apolipoprotein E and renal
disease. Am J Kidney Dis 2004, 43(2):223–233.
2. Saito T, Ishigaki Y, Oikawa S, Yamamoto TT: Etiological significance of
apolipoprotein E mutations in lipoprotein glomerulopathy. Trends
Cardiovasc Med 2002, 12(2):67–70.
3. Hixson JE, Vernier DT: Restriction isotyping of human apolipoprotein E by
gene amplification and cleavage with HhaI. J Lipid Res 1990,
31(3):545–548.4. Saito T, Sato H, Kudo K, Oikawa S, Shibata T, Hara Y, Yoshinaga K, Sakaguchi
H: Lipoprotein glomerulopathy: glomerular lipoprotein thrombi in a
patient with hyperlipoproteinemia. Am J Kidney Dis 1989, 13(2):148–153.
5. Saito T, Matsunaga A, Oikawa S: Impact of lipoprotein glomerulopathy on
the relationship between lipids and renal diseases. Am J Kidney Dis 2006,
47(2):199–211.
6. Sam R, Wu H, Yue L, Mazzone T, Schwartz MM, Arruda JA, Dunea G, Singh
AK: Lipoprotein glomerulopathy: a new apolipoprotein E mutation with
enhanced glomerular binding. Am J Kidney Dis 2006, 47(3):539–548.
7. Ruggenenti P, Cravedi P, Remuzzi G: Thrombotic microangiopathies,
including hemolytic uremic syndrome. In Comprehensive clinical
nephrology. 4th edition. Edited by Floege J, Johnson RJ, Feehally J. Missouri:
Elsevier Saunders; 2010:344–355.
8. Yokomine T, Hirakawa H, Ozawa E, Shibata K, Nakayama T: Pulmonary
thrombotic microangiopathy caused by gastric carcinoma. J Clin Pathol
2010, 63(4):367–369.
9. Mii A, Shimizu A, Masuda Y, Fujino T, Kaneko T, Utsumi K, Arai T, Ishikawa A,
Wakamatsu K, Tajika K, et al: Renal thrombotic microangiopathy
associated with chronic humoral graft versus host disease after
hematopoietic stem cell transplantation. Path Int 2011, 61(1):34–41.
10. Hu WX, Liu ZZ, Chen HP, Zhang HT, Li LS, Liu ZH: Clinical characteristics
and prognosis of diffuse proliferative lupus nephritis with thrombotic
microangiopathy. Lupus 2010, 19(14):1591–1598.
11. Dlott JS, Danielson CFM, Blue-Hnidy DE, McCarthy LJ: Drug-induced
thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a
concise review. Ther Apher Dial 2004, 8(2):102–111.
12. George JN, Raskob GE, Shah SR, Rizvi M, Hamilton S, Osborne S, Vondracek
T: Drug-induced thrombocytopenia: a systematic review of published
case reports. Ann Intern Med 1998, 129(11):886–890.
13. Jackson AM, Rose BD, Graff LG, Jacobs JB, Schwartz JH, Strauss GM, Yang JP,
Rudnick MR, Elfenbein IB, Narins RG: Thrombotic microangiopathy and renal
failure associated with antineoplastic chemotherapy. Ann Intern Med 1984,
101(1):41–44.
14. Akimoto T, Muto S, Ito C, Takahashi H, Takeda S, Ando Y, Kusano E: Clinical
features of malignant hypertension with thrombotic microangiopathy.
Clin Exp Hypertens 2011, 33(2):77–83.
15. Pardo V, Aburano A: Thrombotic microangiopathy and malignant
hypertension. Am J Clin Pathol 1966, 45(5):605–613.
16. van den Born BJ, Honnebier UP, Koopmans RP, van Montfrans GA:
Microangiopathic hemolysis and renal failure in malignant hypertension.
Hypertension 2005, 45(2):246–251.
17. van den Born BJ, van der Hoeven NV, Groot E, Lenting PJ, Meijers JC, Levi
M, van Montfrans GA: Association between thrombotic microangiopathy
and reduced ADAMTS13 activity in malignant hypertension. Hypertension
2008, 51(4):862–866.
18. Shibagaki Y, Fujita T: Thrombotic microangiopathy in malignant
hypertension and hemolytic uremic syndrome (HUS)/ thrombotic
thrombocytopenic purpura (TTP): can we differentiate one from the
other? Hypertens Res 2005, 28(1):89–95.
19. Lip GY, Beevers M, Beevers DG: Complications and survival of 315 patients
with malignant-phase hypertension. J Hypertens 1995, 13(8):915–924.
20. Xin Z, Zhihong L, Shijun L, Jinfeng Z, Huiping C, Caihong Z, Daxi J, Leishi L:
Successful treatment of patients with lipoprotein glomerulopathy by protein
A immunoadsorption: a pilot study. Nephrol Dial Transplant 2009, 24(3):864–869.
21. Russi G, Furci L, Leonelli M, Magistroni R, Romano N, Rivasi P, Albertazzi A:
Lipoprotein glomerulopathy treated with LDL-apheresis (heparin-
induced extracorporeal lipoprotein precipitation system): a case report. J
Med Case Reports 2009, 3:9311.
22. Hamatani H, Hiromura K, Kobatake K, Yoshida H, Kobayashi S, Yoneda N,
Kayakabe K, Matsumoto T, Kuroiwa T, Ueki K, et al: Successful treatment of
lipoprotein glomerulopathy in a daughter and a mother using niceritrol.
Clin Exp Nephrol 2010, 14(6):619–624.
23. Matsunaga A, Furuyama M, Hashimoto T, Toyoda K, Ogino D, Hayasaka K:
Improvement of nephrotic syndrome by intensive lipid-lowering therapy in a
patient with lipoprotein glomerulopathy. Clin Exp Nephrol 2009, 13(6):659–662.
24. Ieiri N, Hotta O, Taguma Y: Resolution of typical lipoprotein
glomerulopathy by intensive lipid-lowering therapy. Am J Kidney Dis
2003, 41(1):244–249.
25. Arai T, Yamashita S, Yamane M, Manabe N, Matsuzaki T, Kiriyama K,
Kanayama Y, Himeno S, Matsuzawa Y: Disappearance of intraglomerular
lipoprotein thrombi and marked improvement of nephrotic syndrome
Wu et al. BMC Nephrology 2013, 14:53 Page 7 of 7
http://www.biomedcentral.com/1471-2369/14/53by bezafibrate treatment in a patient with lipoprotein glomerulopathy.
Atherosclerosis 2003, 169(2):293–299.
26. Fisher DC, Sherrill GB, Hussein A, Rubin P, Vredenburgh JJ, Elkordy M, Ross
M, Petros W, Peters WP: Thrombotic microangiopathy as a complication
of high-dose chemotherapy for breast cancer. Bone Marrow Transplant
1996, 18(1):193–198.
27. Porta C, Danova M, Riccardi A, Bobbio-Pallavicini E, Ascari E: Cancer
chemotherapy-related thrombotic thrombocytopenic purpura: biological
evidence of increased nitric oxide production. Mayo Clin Proc 1999, 74(6):
570–574.
doi:10.1186/1471-2369-14-53
Cite this article as: Wu et al.: A case of lipoprotein glomerulopathy with
thrombotic microangiopathy due to malignant hypertension. BMC
Nephrology 2013 14:53.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
